YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer
Background. Immune checkpoint inhibitors (ICIs) have become a standard care in non-small-cell lung cancer (NSCLC). However, its application to epidermal growth factor receptor (EGFR)-mutant NSCLC patients is confronted with drug resistance. This study aimed to clarify the potential role of Yes1-asso...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Canadian Respiratory Journal |
| Online Access: | http://dx.doi.org/10.1155/2023/4689004 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832546767794601984 |
|---|---|
| author | Ling-Chen Li Xie-Wan Chen Ling Fang Chun-Li Jian Yong-Xin Yu Xing-Yun Liao Jian-Guo Sun |
| author_facet | Ling-Chen Li Xie-Wan Chen Ling Fang Chun-Li Jian Yong-Xin Yu Xing-Yun Liao Jian-Guo Sun |
| author_sort | Ling-Chen Li |
| collection | DOAJ |
| description | Background. Immune checkpoint inhibitors (ICIs) have become a standard care in non-small-cell lung cancer (NSCLC). However, its application to epidermal growth factor receptor (EGFR)-mutant NSCLC patients is confronted with drug resistance. This study aimed to clarify the potential role of Yes1-associated transcriptional regulator (YAP1) in ICIs treatment for EGFR-mutant NSCLC population. Methods. All the clinical data of NSCLC were downloaded from Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) for GSE11969 and GSE72094. Based on YAP1 expression, all the NSCLC patients including the EGFR-mutant and EGFR-wildtype (WT) patients were divided into two groups, YAP1_High and YAP1_Low. Using cBioPortal, genetic alterations were analyzed for identification of immunogenicity in EGFR-mutant NSCLC. MR analysis was used to analyze the hub gene of EGFR. The infiltration of immune cells and the expression of the identified tumor-associated antigens were identified with TIMER. By graph learning-based dimensionality reduction analysis, the immune landscape was visualized. Moreover, survival analysis was performed to verify the predictive value of YAP1 in ICIs treatment for EGFR-mutant NSCLC population using Ren’s research data (NCT03513666). Results. YAP1 was a poor prognostic factor of EGFR-mutant NSCLC population rather than lung adenocarcinoma (LUAD) patients. MR analysis revealed that the EGFR gene regulated YAP1 expression. YAP1 was identified as a hub gene closely associated with immunosuppressive microenvironment and poor prognosis in EGFR-mutant NSCLC population in TCGA LUAD. Tumors with YAP1_High showed an immune-“cold” and immunosuppressive phenotype, whereas those with YAP1_Low demonstrated an immune-“hot” and immunoactive phenotype. More importantly, it was verified that YAP1_High subpopulation had a significantly shorter progression-free survival (PFS) and overall survival (OS) after ICIs treatment in EGFR-mutant NSCLC patients in the clinical trial. Conclusions. YAP1 mediates immunosuppressive microenvironment and poor prognosis in EGFR-mutant NSCLC population. YAP1 is a novel negative biomarker of ICIs treatment in EGFR-mutant NSCLC population. Clinical Trials. This trial is registered with NCT03513666. |
| format | Article |
| id | doaj-art-cefbf99075a74e289026c7edcddeb7a7 |
| institution | Kabale University |
| issn | 1916-7245 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Respiratory Journal |
| spelling | doaj-art-cefbf99075a74e289026c7edcddeb7a72025-02-03T06:47:20ZengWileyCanadian Respiratory Journal1916-72452023-01-01202310.1155/2023/4689004YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung CancerLing-Chen Li0Xie-Wan Chen1Ling Fang2Chun-Li Jian3Yong-Xin Yu4Xing-Yun Liao5Jian-Guo Sun6Cancer InstituteCancer InstituteCancer InstituteCancer InstituteCancer InstituteDepartment of Medical OncologyCancer InstituteBackground. Immune checkpoint inhibitors (ICIs) have become a standard care in non-small-cell lung cancer (NSCLC). However, its application to epidermal growth factor receptor (EGFR)-mutant NSCLC patients is confronted with drug resistance. This study aimed to clarify the potential role of Yes1-associated transcriptional regulator (YAP1) in ICIs treatment for EGFR-mutant NSCLC population. Methods. All the clinical data of NSCLC were downloaded from Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) for GSE11969 and GSE72094. Based on YAP1 expression, all the NSCLC patients including the EGFR-mutant and EGFR-wildtype (WT) patients were divided into two groups, YAP1_High and YAP1_Low. Using cBioPortal, genetic alterations were analyzed for identification of immunogenicity in EGFR-mutant NSCLC. MR analysis was used to analyze the hub gene of EGFR. The infiltration of immune cells and the expression of the identified tumor-associated antigens were identified with TIMER. By graph learning-based dimensionality reduction analysis, the immune landscape was visualized. Moreover, survival analysis was performed to verify the predictive value of YAP1 in ICIs treatment for EGFR-mutant NSCLC population using Ren’s research data (NCT03513666). Results. YAP1 was a poor prognostic factor of EGFR-mutant NSCLC population rather than lung adenocarcinoma (LUAD) patients. MR analysis revealed that the EGFR gene regulated YAP1 expression. YAP1 was identified as a hub gene closely associated with immunosuppressive microenvironment and poor prognosis in EGFR-mutant NSCLC population in TCGA LUAD. Tumors with YAP1_High showed an immune-“cold” and immunosuppressive phenotype, whereas those with YAP1_Low demonstrated an immune-“hot” and immunoactive phenotype. More importantly, it was verified that YAP1_High subpopulation had a significantly shorter progression-free survival (PFS) and overall survival (OS) after ICIs treatment in EGFR-mutant NSCLC patients in the clinical trial. Conclusions. YAP1 mediates immunosuppressive microenvironment and poor prognosis in EGFR-mutant NSCLC population. YAP1 is a novel negative biomarker of ICIs treatment in EGFR-mutant NSCLC population. Clinical Trials. This trial is registered with NCT03513666.http://dx.doi.org/10.1155/2023/4689004 |
| spellingShingle | Ling-Chen Li Xie-Wan Chen Ling Fang Chun-Li Jian Yong-Xin Yu Xing-Yun Liao Jian-Guo Sun YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer Canadian Respiratory Journal |
| title | YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer |
| title_full | YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer |
| title_fullStr | YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer |
| title_full_unstemmed | YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer |
| title_short | YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer |
| title_sort | yap1 as a novel negative biomarker of immune checkpoint inhibitors for egfr mutant non small cell lung cancer |
| url | http://dx.doi.org/10.1155/2023/4689004 |
| work_keys_str_mv | AT lingchenli yap1asanovelnegativebiomarkerofimmunecheckpointinhibitorsforegfrmutantnonsmallcelllungcancer AT xiewanchen yap1asanovelnegativebiomarkerofimmunecheckpointinhibitorsforegfrmutantnonsmallcelllungcancer AT lingfang yap1asanovelnegativebiomarkerofimmunecheckpointinhibitorsforegfrmutantnonsmallcelllungcancer AT chunlijian yap1asanovelnegativebiomarkerofimmunecheckpointinhibitorsforegfrmutantnonsmallcelllungcancer AT yongxinyu yap1asanovelnegativebiomarkerofimmunecheckpointinhibitorsforegfrmutantnonsmallcelllungcancer AT xingyunliao yap1asanovelnegativebiomarkerofimmunecheckpointinhibitorsforegfrmutantnonsmallcelllungcancer AT jianguosun yap1asanovelnegativebiomarkerofimmunecheckpointinhibitorsforegfrmutantnonsmallcelllungcancer |